Aztreonam lysine inhalation solution stabilises lung function decline in patients with cystic fibrosis and moderate to severe lung disease

Chadwick, HK orcid.org/0000-0002-8022-5490, White, H, Shaw, N et al. (5 more authors) (2018) Aztreonam lysine inhalation solution stabilises lung function decline in patients with cystic fibrosis and moderate to severe lung disease. In: Pediatric Pulmonology. NACFC 2018: the 32nd Annual North American Cystic Fibrosis Conference, 18-20 Oct 2018, Denver, CO, USA. Wiley , p. 331.

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2018 Wiley Periodicals, Inc. This is the peer reviewed version of the following article: Chadwick, HK , White, H, Shaw, N et al. (5 more authors) (2018) Aztreonam lysine inhalation solution stabilises lung function decline in patients with cystic fibrosis and moderate to severe lung disease. In: (2018), Poster Session Abstracts. Pediatr Pulmonol, 53: S148-S456, which has been published in final form at https://doi.org/10.1002/ppul.24152. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Accepted: 19 July 2018
  • Published (online): 7 September 2018
  • Published: 7 September 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Translational Medicine (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 16 Oct 2018 11:21
Last Modified: 07 Sep 2019 00:56
Status: Published
Publisher: Wiley
Identification Number: https://doi.org/10.1002/ppul.24152

Share / Export

Statistics